Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
Inhibition of parasite growth is a major objective of blood-stage malaria vaccines. The in vitro assay of parasite growth inhibitory activity (GIA) is widely used as a surrogate marker for malaria vaccine efficacy in the down-selection of candidate blood-stage vaccines. Here we report the first stud...
Main Authors: | Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, Alexander D Douglas, Katharine A Collins, Fenella D Halstead, Sean C Elias, Patrick J Lillie, Kelly Rausch, Joan Aebig, Kazutoyo Miura, Nick J Edwards, Ian D Poulton, Angela Hunt-Cooke, David W Porter, Fiona M Thompson, Ros Rowland, Simon J Draper, Sarah C Gilbert, Michael P Fay, Carole A Long, Daming Zhu, Yimin Wu, Laura B Martin, Charles F Anderson, Alison M Lawrie, Adrian V S Hill, Ruth D Ellis |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3142129?pdf=render |
Similar Items
-
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
by: Gregory E D Mullen, et al.
Published: (2008-08-01) -
Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
by: Ruth D Ellis, et al.
Published: (2012-01-01) -
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
by: Ruth D Ellis, et al.
Published: (2010-01-01) -
CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells
by: Xing N, et al.
Published: (2015-06-01) -
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
by: Meta Roestenberg, et al.
Published: (2008-01-01)